Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PanCov
- Development stage
- Preclinical
- Lead developer
- Linkinvax
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
PanCov is a next-generation pan-sarbecovirus vaccine developed by the French clinical-stage biotechnology company LinKinVax. Designed by the academic Vaccine Research Institute (VRI/INSERM/UPEC), this vaccine aims to provide multi-variant, long-lasting protection against COVID-19. LinKinVax collaborated with French contract manufacturing organizations GTP Bioways and FAREVA for its production, with GTP Bioways also providing cell line development and process development. The development of PanCov received financial support from Bpifrance as part of the PSPC Evidence Project and the French Investing for the Future Programme (PIA).
02
Targets
CD40 (Cluster of differentiation 40 receptor)
Beyond the preview
Go deeper on PanCov.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PanCov.